Literature DB >> 34224057

Long noncoding RNA MGC27382 inhibits proliferation and metastasis of non-small cell lung cancer cells via down-regulating AKT/GSK3β pathway.

Q Li1, S Li2, L Niu3, S Yang4, H Niu5, C Cheng6.   

Abstract

PURPOSE: Persistent abnormal proliferation and long distant metastasis of tumors contribute to high mortality rate in non-small cell lung cancer (NSCLC) patients. Strategies that prevent NSCLC proliferation and/or metastasis have been studied but still need to be further explored. Numerous studies have proved the diversity functions of long noncoding RNAs (lncRNAs) exerted in cancer, including NSCLC. In this study, we aim to identify and investigate the role of novel lncRNAs in NSCLC progression.
METHODS: RNA sequence data were retrieved from the Cancer Genome Atlas (TCGA), differentially expressed lncRNAs (DElncRNAs) were screened out based on the R language, then real-time PCR experiment was introduced to detect the DElncRNA expression levels. A series of experiments including MTT, cell cycle, transwell, and wound healing assays were employed to explore the effect of DElncRNA MGC27382 on cell proliferation and invasion ability.
RESULTS: We detected that DElncRNA MGC27382 is down-regulated in NSCLC tissues and cells. Overexpression of MGC27382 prevented NSCLC cell proliferation via down-regulating cyclin D1 and cyclin E. Moreover, wound healing and transwell assays indicated that the ability of cell invasion and migration could be impaired when cells were treated with MGC27382 overexpression. Further studies demonstrated that MGC27382-mediated inhibition on NSCLC progression can be impaired by LY294002, which is a frequently used inhibitor of AKT/GSK3β pathway.
CONCLUSION: MGC27382 is down-regulated in NSCLC. It exerts an inhibitory role in NSCLC development through suppressing the AKT/GSK3β pathway. Our results indicate that the lncRNA MGC27382 might be a tumor-suppressor gene in NSCLC. Overexpression of MGC27382 is thought to be a potential strategy for overcoming NSCLC progression.
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Cancer development; Migration; Prognosis; Progression; TCGA

Mesh:

Substances:

Year:  2021        PMID: 34224057     DOI: 10.1007/s12094-021-02658-x

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  3 in total

Review 1.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

2.  Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer.

Authors:  Yan-Rong Yang; Shu-Zhi Zang; Chun-Lei Zhong; Yun-Xia Li; Sha-Sha Zhao; Xian-Jun Feng
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Dihydroartemisinin inhibits cell proliferation via AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung cancer cells.

Authors:  Kui Liao; Juan Li; Zhiling Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01
  3 in total
  1 in total

1.  Interfering with ITGB1-DT expression delays cancer progression and promotes cell sensitivity of NSCLC to cisplatin by inhibiting the MAPK/ERK pathway.

Authors:  Dan Li; Xiaoli Liu; Ni Jiang; Di Ke; Qiang Guo; Kui Zhai; Hao Han; Xue Xiao; Tengyang Fan
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.